Publications by authors named "Vu Thuong Le"
Background: The plasma-based epidermal growth factor receptor (EGFR) mutation testing is approved recently to use in clinical practice. However, it has not been used as a prognostic marker yet because of contradictory results.
Aim: This meta-analysis aims to clarify the role of the EGFR-plasma test in prognosis for non-small cell lung cancer (NSCLC) who have mutant tumors and receive EGFR tyrosine kinase inhibitors (TKIs).
Ultra-Deep Massive Parallel Sequencing of Plasma Cell-Free DNA Enables Large-Scale Profiling of Driver Mutations in Vietnamese Patients With Advanced Non-Small Cell Lung Cancer.
Front Oncol
August 2020
Article Synopsis
- Population-specific profiling of cancer gene mutations is essential for better understanding cancer biology and improving diagnostics and treatment tailored to specific groups.
- The study used ultra-deep massive parallel sequencing of plasma cell-free DNA (cfDNA) to analyze mutations in 265 Vietnamese patients with advanced non-small cell lung cancer, offering a less invasive alternative to traditional tumor tissue analysis.
- Although cfDNA testing had lower mutation detection rates, it still identified major mutations in key driver genes that were consistent with findings from tissue sample analysis, highlighting its potential for large-scale genetic profiling in populations with limited access to tumor biopsies.
Objective: This study aimed to identify the influential factors for the sensitivity of epidermal growth factor receptor (EGFR) plasma test in non-small cell lung cancer (NSCLC). The mutations were detected in tumor tissue and matched plasma samples from 125 newly diagnosed adenocarcinoma, clinical-stage IIIB-IV patients, and compared the diagnostic values of EGFR plasma test between groups of clinical characteristics. The influential factors for the sensitivity were identified and assessed by logistic regression.
View Article and Find Full Text PDFArticle Synopsis
- - Comprehensive profiling of mutations in non-small cell lung cancer (NSCLC) is crucial for guiding targeted therapies and improving patient survival, especially in high-incidence regions like Vietnam.
- - A study involving 350 Vietnamese NSCLC patients identified that mutations in the EGFR gene (35.4%) and KRAS gene (22.6%) were the most common, with notable differences compared to other ethnic cohorts.
- - The research found that KRAS mutations were more prevalent in males, while EGFR mutations were more frequent in females, and younger patients (<61 years) showed higher rates of ALK and ROS1 rearrangements.
Background: This study aims to clarify the prognostic role of epidermal growth factor receptor (EGFR) mutations in plasma of non-small cell lung cancer (NSCLC) for resistance to tyrosine kinase inhibitor (TKI), in correlation with clinical characteristics. A total of 94 Adenocarcinoma, clinical stage IV NSCLC patients with either E19del or L858R mutation were admitted to the prospective study from Jan-2016 to Jul-2018. EGFR mutations in plasma were detected by scorpions ARMS method.
View Article and Find Full Text PDF